1. Scrip
  2. >>Business
  3. >>Manufacturing

Huge Samsung BioLogics IPO Reflects Rosy Manufacturing Outlook

 
• By Jung Won Shin

Samsung BioLogics has successful floated in one of South Korea’s largest ever IPOs and appears to be on track to becoming the top global contract manufacturer of biologics amid rising demand from cost-conscious global clients.

Samsung BioLogics’s “mega IPO” has drawn robust interest from institutional investors, reflecting the bright outlook for the contract manufacturing industry, the company’s timely investment to expand production capacity, and a rapidly progressing biosimilar pipeline at its subsidiary.

Samsung BioLogics raised KRW2.5tn ($2.18bn) from the Nov. 2-3 initial public offering, marking the second largest ever IPO in South...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.